Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years
NCT05158777Phase 3Completed
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Feb 2022
- Primary completion
- Nov 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of varicella vaccine live in varicella (VZV) (2 arms), sponsored by Shanghai Institute of Biological Products. Primary endpoints: Seroconversion rate of Hemagglutination Inhibition antibody and Geometric Mean Titer of Hemagglutination Inhibition antibody. Started Feb 2022; status: completed.
02
Drugs
varicella vaccine live
03
Conditions
varicella (VZV)
Beyond the preview
Go deeper on NCT05158777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05158777.